Official Title
Phase II ,III Randomized Double Blind Parallel Arms Clinical Trial of Potential Role of Gum Arabic ( Acacia Senegal) as Immunomodulatory Agent Among COVID 19 Patients in Sudan
Brief Summary

To study the efficacy of Gum Arabic as an immuno modulator and anti-inflammatory agent among COVID 19 seropositive patients..Half of participants will receive Gum Arabic and the other half will receive placebo

Detailed Description

Randomized placebo controlled trial including COVID 19 seropositive patients will be treated with 30 gram per day for 4 weeks, compared to placebo group treated for the same duration in positive COVID 19 patients.

Blood samples will be taken first at base line level, after two weeks and after the intervention after satisfying the inclusion and exclusion criteria. The main objective is to assess the effect of Gum Arabic (acacia Senegal) on immune system among COVID-19 patients. The outcome of this project understand SARS-CoV-2 immune response in COVID patients and the effect of Gum Arabic (Acacia Senegal) consumption to counteract progression of the disease

Not yet recruiting

Dietary Supplement: Acacia Senegal
Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks
Intervention Group
Other Name: Gum Arabic

Dietary Supplement: Pectin
Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks
Control group

Eligibility Criteria

Inclusion Criteria:

- COVID 19 infected as proved by real time PCR (polymerase chain reaction) .( newly diagnosed)

Exclusion Criteria:

- Intubated patients on parental treatment

Eligibility Gender
Eligibility Age
Minimum: 5 Years~Maximum: 90 Years

Dr Babiker, PhD

Shahenaz Satti, MSc

Mustafa KM Nimeiri, MD
Study Chair
Al Neelain University, Faculty of Medicine


Moawia M Mukhtar, PhD
Study Director
University of Khartom , Institute of Endemic Diseases

Al-Neelain University
University of Khartoum
NCT Number
Gum Arabic